Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report

Cervical cancer (CC) ranks fourth for cancer incidences in women after breast cancer, colorectal cancer and lung cancer. There is a steady increase in the incidence of invasive forms of CC in Russia. Over the past quarter of a century, the mortality rate of reproductive age group women with cervical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna E. Protasova, Liubov V. Strakh, Elena I. Lando, Elena V. Sidorkina
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	cervical cancer antiangiogenic therapy pd-1 inhibitor pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1bee8f325e5a4877b199e5b990bdcf02
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1bee8f325e5a4877b199e5b990bdcf02
record_format	dspace
spelling	oai:doaj.org-article:1bee8f325e5a4877b199e5b990bdcf022021-11-30T16:55:01ZMetastatic cervical cancer: clinical experience with pembrolizumab application. Case report1815-14341815-144210.26442/18151434.2021.2.201009https://doaj.org/article/1bee8f325e5a4877b199e5b990bdcf022021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/77941/58530https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Cervical cancer (CC) ranks fourth for cancer incidences in women after breast cancer, colorectal cancer and lung cancer. There is a steady increase in the incidence of invasive forms of CC in Russia. Over the past quarter of a century, the mortality rate of reproductive age group women with cervical cancer has increased by 2 times. The standard treatment options for cervical cancer progression were the regime of paclitaxel plus cisplatin (carboplatin). The addition of an antiangiogenic therapy (bevacizumab) to the standard chemotherapy regimen increases overall survival of only 4%. The response to other lines of chemotherapy does not exceed 10% after the therapy using the combination of paclitaxel + carboplatin + bevacizumab. The results of KEYNOTE-158 trial demonstrated objective responses in 91% of CC patients lasting for more than 6 months in case of application of pembrolizumab 200 mg every 3 weeks in cases of PD-L1 expression (CPS1) with acceptable toxicity. The presented clinical case of successful treatment using pembrolizumab in women with PD-L1 expression in metastatic CC has a beneficial effect on further accumulation of experience and could help to choose the right treatment options in order to increase the efficacy of the therapy and to increase the survival rates for this category of patients.Anna E. ProtasovaLiubov V. StrakhElena I. LandoElena V. SidorkinaIP Habib O.N.articlecervical cancerantiangiogenic therapypd-1 inhibitorpembrolizumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 340-344 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	cervical cancer antiangiogenic therapy pd-1 inhibitor pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cervical cancer antiangiogenic therapy pd-1 inhibitor pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Anna E. Protasova Liubov V. Strakh Elena I. Lando Elena V. Sidorkina Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
description	Cervical cancer (CC) ranks fourth for cancer incidences in women after breast cancer, colorectal cancer and lung cancer. There is a steady increase in the incidence of invasive forms of CC in Russia. Over the past quarter of a century, the mortality rate of reproductive age group women with cervical cancer has increased by 2 times. The standard treatment options for cervical cancer progression were the regime of paclitaxel plus cisplatin (carboplatin). The addition of an antiangiogenic therapy (bevacizumab) to the standard chemotherapy regimen increases overall survival of only 4%. The response to other lines of chemotherapy does not exceed 10% after the therapy using the combination of paclitaxel + carboplatin + bevacizumab. The results of KEYNOTE-158 trial demonstrated objective responses in 91% of CC patients lasting for more than 6 months in case of application of pembrolizumab 200 mg every 3 weeks in cases of PD-L1 expression (CPS1) with acceptable toxicity. The presented clinical case of successful treatment using pembrolizumab in women with PD-L1 expression in metastatic CC has a beneficial effect on further accumulation of experience and could help to choose the right treatment options in order to increase the efficacy of the therapy and to increase the survival rates for this category of patients.
format	article
author	Anna E. Protasova Liubov V. Strakh Elena I. Lando Elena V. Sidorkina
author_facet	Anna E. Protasova Liubov V. Strakh Elena I. Lando Elena V. Sidorkina
author_sort	Anna E. Protasova
title	Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
title_short	Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
title_full	Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
title_fullStr	Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
title_full_unstemmed	Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
title_sort	metastatic cervical cancer: clinical experience with pembrolizumab application. case report
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/1bee8f325e5a4877b199e5b990bdcf02
work_keys_str_mv	AT annaeprotasova metastaticcervicalcancerclinicalexperiencewithpembrolizumabapplicationcasereport AT liubovvstrakh metastaticcervicalcancerclinicalexperiencewithpembrolizumabapplicationcasereport AT elenailando metastaticcervicalcancerclinicalexperiencewithpembrolizumabapplicationcasereport AT elenavsidorkina metastaticcervicalcancerclinicalexperiencewithpembrolizumabapplicationcasereport
_version_	1718406431120556032

Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report

Ejemplares similares